Histiocytic Sarcoma

This is a type of cancer that starts in histiocytes, which are a type of immune cell. It's a rare cancer that usually forms a lump in one area.

Condition

What people with Histiocytic Sarcoma report

Every report comes from a Lived member, sent anonymously.

Have you had Chemotherapy infusion for Histiocytic Sarcoma?

NameHow it went

About Histiocytic Sarcoma

What It Is

Histiocytic sarcoma is a very rare and usually aggressive cancer that starts in histiocytes, the large immune cells (macrophages) that live in tissues and clear away debris and germs. Although it behaves in some ways like a lymphoma and is treated by blood cancer specialists, its cells come from the macrophage family rather than from lymphocytes. It most often appears outside the lymph nodes, in places such as the skin, soft tissue, digestive tract, lungs, spleen or brain. Many people first notice a painless lump or swelling. Others have symptoms from a tumor pressing on nearby organs, or whole-body symptoms such as fever, tiredness, night sweats and weight loss. The disease may be confined to one site (localized) or spread to several sites at diagnosis, and that distinction shapes both treatment and outlook. Histiocytic sarcoma is different from Langerhans cell histiocytosis, Erdheim-Chester disease and Rosai-Dorfman disease. Those are related histiocytic disorders, but they are generally slower and are managed differently. The older name malignant histiocytosis is sometimes still used.

Causes & Risk Factors

In most people, no cause is found. Histiocytic sarcoma can occur at any age, but it is most often diagnosed in people in their 50s and 60s and is slightly more common in men. A meaningful share of cases develop after, or at the same time as, another blood cancer, most often a slow-growing B-cell lymphoma such as follicular lymphoma, or chronic lymphocytic leukemia. In these cases the lymphoma cells appear to change their identity into histiocytic cells while keeping the same underlying genetic changes. This is called secondary histiocytic sarcoma, and it tends to be harder to treat than cases that arise on their own. The tumor cells usually carry acquired gene changes, most often in a cell-growth signaling chain called the MAPK pathway (including genes such as BRAF, MAP2K1 and KRAS). These changes develop in the tumor itself; they are not inherited, and there is no known lifestyle cause or way to prevent the disease.

How It's Diagnosed

Diagnosis depends on a biopsy, in which a sample of the tumor is removed and examined under a microscope. Because histiocytic sarcoma is rare and its cells can look like many other cancers and some noncancerous conditions, pathologists use a panel of special stains that detect proteins on the cells (immunohistochemistry). Markers typical of macrophages support the diagnosis, while other markers help rule out lymphoma and other look-alike cancers. A second opinion from a pathologist experienced in blood cancers or histiocytic disorders is often worthwhile. An international expert consensus recommends broad genetic (molecular) testing of the tumor, because finding a change such as a BRAF or MAP2K1 mutation can open the door to targeted medicines. The tumor may also be tested for PD-L1, a protein that can predict whether immunotherapy might help. Doctors also check for any past or current lymphoma or leukemia, since that changes how the disease is understood and treated. To see how far the disease has spread, a PET-CT scan (positron emission tomography combined with computed tomography) is usually the most useful imaging test. It pairs detailed cross-sectional images with a tracer that highlights active tumor, and the same scan is later used to judge how well treatment is working. Blood tests help assess overall health before treatment.

Treatment Options

There is no single standard treatment, because the disease is too rare for large clinical trials. Treatment is planned around whether the cancer is localized or widespread, which organs are involved, the tumor's genetic findings and the person's overall health, ideally at a center with experience in histiocytic disorders. For disease confined to one site, surgery to remove the whole tumor with a rim of healthy tissue is the main treatment and offers the best chance of long-term control or cure. Radiation therapy may be added when the edges of the removed tissue still contain cancer and more surgery is not possible, or used on its own when surgery would be too risky. Radiation can also relieve pain or pressure from a tumor. When the disease is in several places, the usual first step is chemotherapy borrowed from lymphoma treatment, most often CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone), sometimes with etoposide. Responses occur, but the cancer often returns, and other chemotherapy combinations may follow. Newer approaches depend on what the tumor's testing shows. Targeted medicines that block the MAPK pathway, such as BRAF inhibitors (vemurafenib, dabrafenib) or MEK inhibitors (trametinib, cobimetinib), have produced strong responses in some people whose tumors carry matching mutations. Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which help the immune system attack cancer, have led to lasting responses in some tumors with high PD-L1 levels. None of these medicines is approved by the US Food and Drug Administration (FDA) specifically for histiocytic sarcoma, and the evidence comes mainly from individual case reports, so they are often used after chemotherapy or within clinical trials. A stem cell transplant is sometimes considered for disease that returns or does not respond, but experience with it is limited. For secondary histiocytic sarcoma, the team also takes into account the earlier lymphoma or leukemia and its treatment.

What to Expect

Histiocytic sarcoma is usually a serious diagnosis. In large cancer registry studies, half of people lived about six months or less after diagnosis, and most deaths are from the cancer progressing. These figures describe groups, though, and individual outlook varies widely. People with a single tumor that can be completely removed fare much better, and some remain free of disease for many years. Outlook tends to be poorer when the disease is widespread, involves the brain or liver, or arises from an earlier lymphoma. Treatment is often intensive. Chemotherapy brings tiredness, low blood counts and a higher risk of infection, and people may need frequent clinic visits and scans. Because so few specialists see this cancer, travel to a referral center or virtual consultations may be part of care. After treatment, regular follow-up with examinations and scans, often PET-CT, watches for any return of the disease, which matters because relapse is common. Given the uncertain outlook, many people find it helpful to discuss goals of care early, involve palliative care for symptom relief alongside treatment, and ask about clinical trials and support for family caregivers.

When to Seek Help

See a doctor about a lump or swelling that persists or keeps growing, or about unexplained fever, drenching night sweats or weight loss, particularly if you have had lymphoma or leukemia. If you are receiving chemotherapy, call your treatment team right away for a fever of 100.5 F (38 C) or higher, shaking chills or other signs of infection, because infections during cancer treatment can become life threatening quickly. Also contact the team promptly about new or worsening pain, a new lump, or new neurological symptoms such as headaches, weakness or confusion, since these can signal that the cancer is growing or has spread.

Questions to Ask Your Doctor

  1. 1.Is my disease localized enough that surgery could remove it completely, and would radiation add anything?
  2. 2.Has my tumor had broad genetic testing and PD-L1 testing, and do the results point to a targeted medicine or immunotherapy?
  3. 3.Is my histiocytic sarcoma related to a previous lymphoma or leukemia, and how does that change the plan?
  4. 4.Are there clinical trials or specialist centers in histiocytic disorders that we should contact?
  5. 5.What does the outlook look like in my situation, and how can palliative care help alongside treatment?

Last reviewed • Oct 2026

Educational content, not medical advice.